Dataset Information
One year follow-up of children and adolescents with chronic immune thrombocytopenic purpura (ITP) treated with rituximab.
Ontology highlight
ABSTRACT: Background
We previously showed in a prospective study that rituximab appears to be effective in some children and adolescents with severe chronic immune thrombocytopenia. Eleven of 36 patients achieved and maintained platelet counts over 50,000/mm(3) within the first 12 weeks. These patients were followed for the next year.Methods
Platelet counts were monitored monthly and all subsequent bleeding manifestations and need for further treatment was noted.Results
Eight of the 11 initial responders maintained a platelet count over 150,000/mm(3) without further treatment intervention. Three patients had a late relapse. One initial non-responder achieved a remission after 16 weeks, and two additional patients maintained platelet counts around 50,000/mm(3) without the need for further intervention.Conclusions
Rituximab resulted in sustained efficacy with platelet counts of 50,000/mm(3) or higher in 11 of 36 patients (31%).
SUBMITTER: Mueller BU
PROVIDER: S-EPMC5752113 | biostudies-literature | 2009 Feb
REPOSITORIES: biostudies-literature
Publications
One year follow-up of children and adolescents with chronic immune thrombocytopenic purpura (ITP) treated with rituximab.
Pediatric blood & cancer 20090201 2
<h4>Background</h4>We previously showed in a prospective study that rituximab appears to be effective in some children and adolescents with severe chronic immune thrombocytopenia. Eleven of 36 patients achieved and maintained platelet counts over 50,000/mm(3) within the first 12 weeks. These patients were followed for the next year.<h4>Methods</h4>Platelet counts were monitored monthly and all subsequent bleeding manifestations and need for further treatment was noted.<h4>Results</h4>Eight of th ...[more]
